Examination of treatment pattern differences by race

Mental Health Services Research

Volumn 5, Issue 4, 2003, Pages 241-250

  Mark, Tami L ^a   Palmer, Liisa A ^a   Russo, Patricia A ^a   Vasey, Joseph ^b  

^a MEDSTAT GROUP   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Access; African American; Atypical antipsychotic; Race; Schizophrenia

Indexed keywords

ANTIPARKINSON AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; CAUCASIAN; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HEALTH PROGRAM; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL HEALTH CARE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEGRO; OUTPATIENT DEPARTMENT; PARANOIA; PRESCRIPTION; PSYCHOTHERAPY; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SELF REPORT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; UNITED STATES;

AFRICAN AMERICANS; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MENTAL HEALTH SERVICES; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF ADMINISTRATION; SEX FACTORS; UNITED STATES;

EID: 0345328832     PISSN: 15223434     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026281118990     Document Type: Review

References (51)

1. Adebimpe, V. R. (1994). Race, racism, and epidemiological surveys. Hospital and Community Psychiatry, 45, 27-31.
2. Akutsu, P. D., Snowden, L. R., & Organista, K. C. (1996). Referral patterns to ethnic-specific and mainstream mental health programs for Hispanics and non-Hispanic whites. Journal of Counseling Psychology, 43, 56-64.
3. American Psychiatric Association. (1997). Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry, 154 (Suppl. 4), 1-63.
4. American Psychiatric Association. (2001, December 15). Schizophrenia. Retrieved from www.psych.org
5. Awad, A. G., Voruganti, L. N. P., & Heslegrave, R. J. (1997). Measuring quality of life in patients with schizophrenia. Pharmacoeconomics, 11, 32-47.
6. Baillargeon, J., & Contreras, S. A. (2001). Antipsychotic prescribing patterns in the Texas prison system. Journal of the American Academy of Psychiatry Law, 29, 48-53.
7. Chiles, J. A., Miller, A. L., Crismon, M. L., Rush, A. J., Krasnoff, A. S., & Shon, S. S. (1999). The Texas Medication Algorithm Project: Development and implementation of the schizophrenia algorithm. Psychiatric Services, 50, 69-74.
8. Chung, H., Mahler, J. C., & Kakuna, T. (1995). Racial differences in the treatment of psychiatric inpatients. Psychiatric Services, 46, 586-591.
9. Citrome, L., Levine, J., & Allingham, B. (1996). Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacology Bulletin, 32, 321-326.
10. Dixon, L. B., Lehman, A. F., & Levine, J. (1995). Conventional antipsychotic medications for schizophrenia. Schizophrenia Bulletin, 21, 567-577.
11. First, M. B. (1996). Effective use of the Global Assessment of Functioning (GAF) Scale in a managed care environment. New York: Columbia University Press.
12. Flaskerud, J. H., & Hu, L. (1992). Relationship between ethnicity and psychiatric diagnosis. The Journal of Nervous and Mental Disease, 180, 296-303.
13. Glazer, W. M., & Johnstone, B. M. (1997). Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. Journal of Clinical Psychiatry, 58 (Suppl. 10), 50-54.
14. Glazer, W. M., Morgenstern, H., & Doucetter, J. (1994). Race and tardive dyskinesia among outpatients at a CMHC. Hospital and Community Psychiatry, 45, 38-42.
15. Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. Bethesda, MD: National Institute for Mental Health (NIMH).
16. Häfner, H., & an der Heiden, W. (1997). Epidemiology of schizophrenia. Canadian Journal of Psychiatry, 42, 139-151.
17. Haley, J. C., Russo, P. A., & Johnstone, B. M. (1998). Prospective, naturalistic outcomes measurement: The Schizophrenia Care and Assessment Program (SCAP). Value in Health, 1, 89.
18. Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984). The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin, 10, 388-398.
19. Kapur, S., & Remington, G. (2001). Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia. Annual Review of Medicine, 52, 503-517.
20. Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
21. Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., Wittchen, H.-U., & Kendler, K. S. (1994). Lifetime and 12-month prevalence of DSM-III-R disorders in the United States. Archives of General Psychiatry, 51, 8-19.
22. Kuno, E., & Rothbard A. B. (2002). Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. American Journal of Psychiatry, 159(4), 567-572.
23. Lawson, W. B. (1996). Clinical issues in the pharmacotherapy of African Americans. Psychopharmacology Bulletin, 32, 275-279.
24. Lawson, W. B., Hepler, N., Holladay, J., & Cuffel, B. (1994). Race as a factor in inpatient and outpatient admissions and diagnosis. Hospital and Community Psychiatry, 45, 72-74.
25. Lehman, A. F. (1996). Evaluating outcomes of treatments for persons with psychotic disorders. Journal of Clinical Psychiatry, 57 (Suppl. 11), 61-67.
26. Lehman, A., & Steinwachs, D. (1998). Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) client survey. Schizophrenia Bulletin, 24, 1-10.
27. Lin, K. M., Poland, R. E., Wan, Y. J., Smith, M. W., & Lesser, I. M. (1996). The evolving science of pharmacogenetics: Clinical and ethnic perspectives. Psychopharmacology Bulletin, 32, 205-217.
28. Mark, T. L., Dirani, R., Slade, E., & Russo, P A. (2002). Access to new medications to treat schizophrenia. The Journal of Behavioral Health Services and Research, 29, 15-29.
29. Martin, B. C., Miller, L. S., & Kotzan, J. A. (2001). Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: Current trends and five year time series forecasts. Schizophrenia Research, 47, 281-292.
30. McCombs, J. S., Nichol, M. B., Stimmel, G. L., Shi, J., & Smith, R. R. (1999). Use patterns for antipsychotics medications in Medicaid patients with schizophrenia. Journal of Clinical Psychiatry, 60 (Suppl 19), 5-11.
31. McEvoy, J. P., Scheifler, P. L., & Frances, A. (Eds.). (1999). The expert consensus guideline series: Treatment for schizophrenia 1999. Journal of Clinical Psychiatry, 60 (Suppl. 11), 1-80.
32. Montgomery, S. A., & Asberg, M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389.
33. Pingitore, D., Snowden, L. R., Sansome, R., & Klikman, M. (2001). Persons with depressive symptoms and the treatments they receive: A comparison of primary care physicians and psychiatrists. International Journal of Psychiatry in Medicine, 31, 41-60.
34. Remington, G., & Khramov, I. (2001). Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics. Progress in Neuropsychopharmacology and Biological Psychiatry, 25, 363-369.
35. Robins, L., & Regier, D. A. (1991). Psychiatric disorders in America: The Epidemiologic Catchment Area Study. New York: The Free Press.
36. Rupp, A., & Keith, S. J. (1993). The costs of schizophrenia. Psychiatric Clinics of North America, 16, 413-423.
37. Segal, S., Bola, J., & Watson, M. (1996). Race, quality of care and antipsychotic prescribing practices in psychiatric emergency services. Psychiatric Services, 47, 282-286.
38. Shore, D. (1998). Recent developments in atypical antipsychotics medications. Schizophrenia Bulletin, 24, 33.
39. Simon, R. J., Fleiss, J. L., Gurland, B. J., Stiller, P. R., & Sharpe, L. (1973). Depression and schizophrenia in hospitalized black and white mental patients. Archives of General Psychiatry, 28, 509-512.
40. Sue, S., Zane, N., & Young, K. (1994). Research on psychotherapy on culturally diverse populations. In A. Bergin & S. Garfield (Eds.), Handbook of psychotherapy and behavior change (4th ed., pp. 783-817). New York: Wiley.
41. Takeuchi, D. T., & Cheung, M. K. (1998). Coercive and voluntary referrals: How ethnic minority adults get into mental health treatment. Ethnicity and Health, 3, 149-158.
42. Tattan, T. M., & Creed, F. H. (2001). Negative symptoms of schizophrenia and compliance with medication. Schizophrenia Bulletin, 27, 149-155.
43. Trierweiler, S. J., Neighbors, H. W., Munday, C., Thompson, S. E., Binion, V. J., & Gomez, J. P. (2000). Clinician attribution associated with diagnosis of schizophrenia in African American and non-African American patients. Journal of Consulting and Clinical Psychology, 68, 171-175.
44. U.S. Department of Health and Human Services. (1999). In H. H. Goldman, P. Rye, & P. Sirovatka (Eds.), Mental health: A Report to the Surgeon General. Rockville, MD: Author.
45. Walkup, J. T., McAlpine, D. D., Olfson, M., Labay, L. E., Boyer, C., & Hansell, S. (2000). Patients with schizophrenia at risk for excessive antipsychotic dosing. Clinical Psychiatry, 61, 344-348.
46. Wang, P. S., Demler, O., & Kessler, R. C. (2002). Adequacy of treatment for serious mental illness in the United States. American Journal of Public Health, 92, 92-98.
47. Weiden, P., Aquila, R., & Standard, J. (1996). Atypical antipsychotics drugs and long-term outcome in schizophrenia. Journal of Clinical Psychiatry, 57 (Suppl. 11), 53-60.
48. Weinick, R. M., Zuvekas, S. H., & Cohen, J. W. (1996). Racial and ethnic differences in access to and use of health care services, 1977 to 1996. Medical Care Research and Review, 57 (Suppl. 1), 36-54.
49. Whaley, A. L. (1997). Ethnicity/race, paranoia and psychiatric diagnoses: Clinician bias versus sociocultural differences. Journal of Psychopathology and Behavioral Assessment, 19, 1-20.
50. Williams, D. R., Lavizzo-Mourey, R., & Warren, R. (1994). The concept of race and health status in America. Public Health Reports, 109, 26-41.
51. Young, A. S., Sullivan, G., & Duan, N. (1999). Patient, provider, and treatment factors associated with poor-quality care for schizophrenia. Mental Health Services Research, 1, 201-211.